![]() ![]() Interference is what makes soap bubbles and peacock feathers look so colorful. When peaks meet up with troughs, the peaks and troughs cancel out, creating a smaller wave and dimmer light. He showed that when the peaks of two waves line up, they add together, creating a bigger wave and brighter light. A scientist named Thomas Young demonstrated this really well in a famous experiment called the “ two slit experiment”. Interference happens when two waves meet in the same space and affect each other. Wavelength is the distance between one peak in the wave and the next. Team Light replies, “Light travels as a wave, with high peaks and low troughs just like waves on the ocean. She then asks, “Could you please explain what those words mean?” “Correct!” says the referee, giving Team Light a point. Looking around proudly, the captain adds, “This means we can experience interference or diffraction.” Team Light is the first to hit the buzzer. The referee introduces the rules: teams score points by telling the audience about things that make their topic special. On the right is “Team Sound,” wearing DJ hats and t-shirts with musical notes. On the left side is “Team Light,” wearing t-shirts with an image of a lightbulb. There are two teams of three people each, sitting at desks facing each other, with a referee in between them. Imagine being in the audience at a TV studio, waiting for a quiz show to start. The future of shaping and designing sound is in the making! Maybe someday, sound experts will even teach something to light experts! We will tell you about acoustic metamaterials, an emerging technology that is quickly becoming part of our loudspeakers, our shows, our cars, our public spaces, and our hospitals-all the places where we want control over sound and noise. So, why do we not have lenses or displays for sound? Or do we? This article will tell the story of how sound technology is catching up with light technology. Light and sound are very similar: they are both waves, and they both have particles associated with them. Lenses and holograms are part of our everyday lives. The science of light manipulation started with the ancient Greeks, so we have had many years to develop it.
0 Comments
![]() “The urgency and necessity of developing and delivering our COVID-19 vaccine required our R&D teams to find new and exciting ways to use our novel vaccine technology to rapidly progress our science and maximize our impact for humanity,” said Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC. ![]() In parallel, the Company forged a global supply network that included Aspen and partners in the U.S., Europe and India, and entered into advance purchase agreements with Gavi, on behalf of the COVAX Facility, and AVAT to supply 420 million vaccine doses to low- and middle-income countries (LMICs) through 2022. The “Sisonke” study made the Johnson & Johnson COVID-19 vaccine available to 500,000 frontline healthcare workers across the country. We complemented this by supporting a large-scale implementation study for our vaccine in South Africa. Johnson & Johnson supported the development of its vaccine with a truly global and inclusive clinical research program that studied the vaccine across the U.S., Europe, Africa, Asia and Latin America as we sought to generate evidence across multiple geographies and diverse, at-risk populations, including in resource-limited settings. Johnson & Johnson’s Equitable Response to COVID-19Ī commitment to global equity has guided the Company’s response since the beginning of the pandemic, starting with the decision to pursue a vaccine that can provide protection with a single dose and be easily stored and distributed with standard refrigeration globally, including in resource-limited, rural or remote settings. Initially by choosing Aspen, located in Africa, as a core manufacturing partner, and then by showing resolve and dedication to a technical transfer process during the most stringent lockdown periods of the COVID outbreak.” Through this agreement and their earlier actions, Johnson & Johnson has demonstrated its commitment to our continent. “This has been achieved through tremendous teamwork and collaboration between Johnson & Johnson and Aspen. “With the conclusion of this agreement, our vision for Africa’s own vaccine has become a reality,” said Stephen Saad, Aspen Group Chief Executive. The agreement enables Aspen, using COVID-19 vaccine drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine and make doses available to the public sector in Africa, including all 55 Member States of the African Union and key multilateral entities supporting Africa’s COVID-19 vaccination drive, inclusive of the African Vaccine Acquisition Trust (AVAT), and the COVAX Facility. As one of our contract manufacturers since November 2020, Aspen has been a significant supplier within the Johnson & Johnson global network. To date, Johnson & Johnson has shipped more than 200 million vaccine doses to Africa through a combination of our advance purchase agreements with the African Vaccine Acquisition Trust, South Africa and Gavi, the Vaccine Alliance, on behalf of the COVAX Facility, along with government donations. We’re proud to take our long-standing collaboration with Aspen to the next level, to continue to address the COVID-19 threat and lay the groundwork for a healthier, more secure future for people in Africa.” “We initiated clinical trials in all regions of the world to generate evidence across multiple geographies and diverse, at-risk populations and forged a strategic partnership with Aspen in Africa and others to manufacture our vaccine globally. “From the outset of this pandemic we aimed to develop a simple-to-use and accessible vaccine that could be transported around the world through standard vaccine distribution channels,” said Martin Fitchet, M.D., Head of Global Public Health, Johnson & Johnson, Cilag GmbH International. Our response to the COVID-19 pandemic has been guided by the conviction that unless everyone is safe, no one is safe, which is why we worked to develop and deliver a vaccine that can protect the health of everyone, everywhere. Currently, only about 12 percent of people in Africa are fully vaccinated, which is well below the World Health Organization’s target of 70 percent population coverage for all countries. ![]() ![]() NEW BRUNSWICK, NJ (March 8, 2022) – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the completion of a landmark agreement between Janssen Pharmaceuticals, Inc., and manufacturer Aspen SA Operations (Pty) Ltd, based in South Africa, to enable the first COVID-19 vaccine to be manufactured and made available by an African company for people living in Africa, with the goal of increasing COVID-19 vaccination rates across the continent.Įxpanding global vaccination coverage is critically important to controlling the COVID-19 pandemic and reducing the risk of emergence of new SARS-CoV-2 variants. ![]() How to reverse an array in Java? ( solution).5 Books to Learn Data Structure and Algorithms in-depth ( books). ![]()
|
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |